Orexo Ab · OMXSTO:ORX
Orexo Ab — Investor Day (November 2020)
13 slides from Orexo Ab's investor day presentation, November 2020
Slide 1: A commercial stage pharma company with an exciting pipeline
1 A commercial stage pharma company with an exciting pipeline OTC Markets Swedish Investor Day, Nov. 20 Bob DeLuca, President Orexo US Inc.
Slide 2: Legal disclaimer
2 Legal disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Or
Slide 3: Orexo in brief
3 Orexo in brief Comments Q2 Strong cash generation Net Revenue LTM 1 Orexo is a Swedish Addresses unmet needs Wholly owned commercial from lead product pharmaceutical company with among patients and operations in the US, incl. nearly 30 years of experience healthcare systems within the lead pharma
Slide 4: Orexo addressing OUD with a growing product offering
4 Orexo addressing OUD with a growing product offering Fatal overdoses have surged due to synthetic opioids 1 120000 8,900,000 Number of deaths 100000 are misusing opioids2 80000 60000 40000 20000 6,100,000 0 2017 2018 2019 2020 2021 2022 2023 Total overdose deaths All opioid overdoses Synthetic opi
Slide 5: Commercial products and development pipeline
5 Commercial products and development pipeline Approved and/or Launched Product or Project/Indication/Technology Partners Exploratory Preclinical Clinical development phases Registration US EU RoW Commercial products Zubsolv® Opioid Use Disorder (OUD) / Sublingual platform Abstral® Breaktrough Cance
Slide 6: Orexo's development pipeline building on the proprietary AmorphOX drug delivery technology
6 Orexo´s development pipeline building on the proprietary AmorphOX® drug delivery technology Wide applicability Validated in humans Excellent stability ✓ Powder technology that works ✓ Superior pharmacokinetic ✓ Excellent stability even under with a broad scope of small and accelerated conditions a
Slide 7: OX124 - a high-dose naloxone rescue medication
7 OX124 - a high-dose naloxone rescue medication designed to reverse the most powerful synthetic opioids Intranasal powder delivery of naloxone built on AmorphOX ® OX124 differentiation & competitive advantages Rapid absorption and substantially higher plasma Small in Built-in desiccant to The usage
Slide 8: Naloxone market has grown significantly and there is a need for a product like OX124
8 Naloxone market has grown significantly and there is a need for a product like OX124 ~25-40 M Doses Distributed (2024 estimate) Up From ~17 M Doses (2021 estimate) OTC Drives Wider Distribution 2024 Estimated Market Size: ~ USD >USD 550 M – with Narcan OTC being a clear market leader Hospitals/ Co
Slide 9: OX640 – an intranasal powder-based epinephrine treatment of allergic reactions
9 OX640 – an intranasal powder-based epinephrine treatment of allergic reactions, incl. anaphylaxis Improved stability and a more sustainable product Comparative stability study at 40°C/75% RH1 Preservative-free OX640 EpiPen® Needle-free and 110 easy-to-use (which may cause allergic reactions) 105 E
Slide 10: Strategic initiatives based on a sustainable foundation
10 Strategic initiatives based on a sustainable foundation Improving access to treatment Capitalizing on the AmorphOX® drug delivery Growing revenues and profit contributions technology Key milestones and focus areas going forward • Maintain Zubsolv® revenues • Expand reimbursement of Zubsolv in the
Slide 11: Thanks
You can also,follow Orexo on LinkedIn, X and YouTube and also read our blog in .X (>
Slide 12: APPENDIX
Oorex APPENDIX
Slide 13: Q3 2024 legal update
13 Q3 2024 Zubsolv® patent dispute vs Sun Pharmaceuticals US government agency investigation related to legal Zubsolv update ✓ In Q1 2023 the trial was conducted in the US ✓ On July 14, 2020, Orexo became aware District Court for the District of New Jersey. of an investigation by the US authorities